Good deal! This could be what the otc needs to spur a run

👻🤠🤑

My understanding through the cool off rule by the sec they have to trade for a year on the otc before uplisting to the NASDAQ. With no RS they intend on moving up to the OTCQB or QX organically. This will be fun 🤩

I don’t ever remember a OTC Rm into a company with revenue OF $300 million

Yes! Cipro and augmentin have been around for a long time.
It will take a while for the bugs to become resistant to this one.
And yes the doctors are the ones that caused this over prescribing. They give it away like candy and use it as a prophylactic after just about every surgery

I think we here something before the end of the year

I think the OTC is coming alive. Hopefully we get some news

👍🙏

https://x.com/raadr__

New tweet out. “Thanks to the support of everyone , from the RAADR team to the shareholders,we shall continue to increase shareholder value as we stated with no reverse split. We will uplist to nasdaq and continue on a journey of success and growth.And I hope everyone has a great weekend as well”

AI Overview
According to recent updates, the FDA appears to be leaning towards approving Sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs), but with significant concerns regarding antimicrobial resistance and the need for careful monitoring through post-marketing surveillance to ensure appropriate usage; the FDA Advisory Committee acknowledged the potential benefit for a subset of patients while emphasizing the importance of managing off-label use and potential impact on antimicrobial resistance if approved.

Sounds like the drug works well. FDA has to have the appropriate usage on the label it sounds like

Stock cancellation, no RS and over $300 million in revenue. What more do penny players want 😆

AWESOMENESS

Awesome

Being how much revenue is in place and potentially trading for a while on the upper tier of the OTC maybe they buy back shares and cancel some

Absolutely

https://mexedia.com/en/download/consolidated-financial-report-as-at-31-december-2023/?wpdmdl=8876&refresh=67125c94a04d01729256596

Nice to see you again my friend. Yes please 🤑🤑

Yes sir! Hoping here :)

The NYSE and Amex proposals would have required that a company completing a reverse merger with a SHELL company “season” its trading on an over-the-counter market or another national securities exchange for 12 months before an “uplisting” would be permitted to either of these exchanges. The only exception would be if the company were conducting a large public offering to raise net proceeds of at least $40 million in a so-called “firm commitment” transaction. A broker-dealer acting as underwriter in raising this money must have substantial capital in order to be permitted to conduct a firm commitment offering. Strangely, while every other listing standard for NYSE is higher than those for Amex, the $40 million minimum offering to avoid seasoning was the same in both the NYSE and Amex proposals.

The proposals also required that before uplisting after a year of trading over-the-counter, the company’s stock must have been trading for a “sustained period” at the minimum price required to be listed. Finally, the company must have completed one full year of regular SEC filings. Interestingly, the proposal suggests that it will treat as reverse mergers combinations with certain public companies that would not technically qualify as shells under the SEC definition. If a company is not particularly active, they might consider it as a shell for purposes of seasoning.

https://journals.law.harvard.edu/hblr/2012/03/reverse-merger-seasoning/

This is not a shell company so it might be different?

Trend is our friend

Trading at $6 a share https://www.investing.com/equities/airtime-partecipazioni

We are confident that our shareholders will be incredibly pleased on the structure of the transaction and the amazing opportunity to create immense shareholder value together.

https://www.morningstar.com/news/accesswire/931234msn/new-raadr-inc-president-and-director-issues-shareholder-letter-on-recent-acquisition-transaction

https://www.linkedin.com/company/mexedia-spa

Based on the yearly revenue of $300 million plus it could easily push this into multi pennies for qualification for the OTCQB

I do believe on a reverse takeover or merger into a OTC stock they have to trade on the otc for a year before moving up to the Nasdaq. Probably OTCQB OR QX

TRANSLATION: Consolidate global presence and expand growth opportunities through a strategy of targeted acquisitions and strengthening the solution portfolio
High margin SaaS (software as a Service).
These are the objectives with which Mexedia, an Italian tech company listed on Euronext Growth Paris, completed the transaction which led to the acquisition of its operating units in the United States and Ireland by the American Raadr (listed on OTCMarkets). The transaction was carried out through a reverse takeover.

The operation also includes the planning of an uplisting of Raadr to the Nasdaq with the aim of accessing greater liquidity and opportunities in the capital market.
The operation is part of the growth strategy of Mexedia, which in 2023 recorded a consolidated turnover of over 323 million euros, with an increase of 130% compared to 2022, and an EBITDA of 13.8 million euros (+65% compared to 2022).

With the acquisition, new Raadr leaders were appointed: Orlando Taddeo, founder and CEO of Mexedia, was appointed President of Raadr, Daniel Contreras assumed the role of Chief Executive Officer and Daniel Gilcher that of Chief Financial Officer.

Among the key points of the transaction: the transaction values ??Mexedia's voice business at $60 million, including operations in the United States and Ireland, Mexedia retains 75% control of Raadr through preferred equity, with anti-dilution clauses . Fund-raising is planned between
¡ 10 and 20 million dollars for Raadr, which will begin immediately. Mexedia will have the option to deconsolidate its stake by distributing Raadr shares to its shareholders once the transaction is completed.
(TELEBORSA) 15-10-2024 13:48

Could be bottom here

Any believers their drug gets approved Oct 25th?
Should fly if it does

They purchased the shell but haven’t merged into it yet!

Good question

Same here

“In the third quarter, we continued to effectively execute on the strategic reset we initiated earlier in the year, and we are confident in the momentum we have moving into the fourth quarter to finish the year strong”

https://www.businesswire.com/news/home/20241010657314/en/sonendo-inc.-announces-preliminary-third-quarter-2024-financial-results/

Yeah let’s rock and roll lol

I think it has to be something different other than a new restaurant or more pasta sauce.
Either like you say, a new celebrity deal or sell the shell and go a new direction

Yeah I thought think they should definitely give shareholders some news of a plan

Gotta get some love here sooner or later

Looks like it was a fake out

Yesterday must have been a gambler or an insider loading